<DOC>
	<DOCNO>NCT02327403</DOCNO>
	<brief_summary>Background : Proteinuria develop 30 % kidney transplant recipient strong predictor graft loss . The amount proteinuria direct correlation risk graft failure . Novel therapy urgently need reduce proteinuria prevent graft loss transplant recipient , since ACE inhibitor carry number limitation transplant setting , include significant reduction renal function , anemia hyperkalemia . Preliminary data : B7-1 express significant level 10 % kidney allograft biopsy predominance patient proteinuria . Hypothesis : We hypothesize B7-1 target therapy may reduce proteinuria improve graft survival proteinuric transplant recipient B7-1 stain allograft . In addition , absence CNI nephrotoxicity potential protective effect Belatacept DSA production may benefit subset transplant patient . Objectives : Primary : Determine effect Belatacept conversion reduce proteinuria 25 % 12 month renal transplant recipient ( ≥1gram/d ) either B7-1-positive negative kidney biopsy . Secondary : Assess effect Belatacept conversion percent change renal function baseline 12 month ; donor-specific anti-HLA antibody presence intensity ( MFI ) ; correlation B7-1 positivity immunofluorescence biopsy B7-1-expression urine extracellular vesicle ; adverse event ; acute rejection episode ; blood pressure control ; new onset diabetes ; hyperlipidemia ; graft survival ; patient survival .</brief_summary>
	<brief_title>Belatacept Conversion Proteinuric Kidney Transplant Recipients</brief_title>
	<detailed_description>A total 36 patient recruit .</detailed_description>
	<mesh_term>Proteinuria</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>1 . Male female adult kidney transplant recipient older 18 year old 2. eGFR ≥30 ml/min 3 . ≥6 month transplantation 4 . Proteinuria ≥1 gram/day spot urine protein/creatinine ratio 5 . Available biopsy specimen B71 stain recruitment time . 6 . Ability provide write informed consent study . 7 . Maintenance immunosuppression CNI ( cyclosporine tacrolimus ) , antiproliferative agent ( azathioprine , MMF MPA ) either steroid . 1 . Age &lt; 18 year 2. eGFR &lt; 30 ml/min 3. active acute cellular rejection ( ACR ; high borderline ) ACR previous 6 month ; active acute antibodymediated rejection 4. recurrent FSGS 5 . EBV IgG negative 6. patient mTOR inhibitor ( e.g . Everolimus , Sirolimus ) 7. patient CNI ( cyclosporine tacrolimus ) steroid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Proteinuria</keyword>
	<keyword>Kidney transplantation</keyword>
	<keyword>Allograft dysfunction</keyword>
	<keyword>B7-1</keyword>
	<keyword>Belatacept</keyword>
</DOC>